SRP9

Summary

SRP9 (signal recognition particle 9, HGNC:11304) is a protein-coding gene on chromosome 1q42.12, encoding Signal recognition particle 9 kDa protein (P49458). Component of the signal recognition particle (SRP) complex, a ribonucleoprotein complex that mediates the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). It is a common-essential gene (DepMap: required in 95.4% of cancer cell lines).

Predicted to enable RNA binding activity and signal recognition particle binding activity. Predicted to be involved in SRP-dependent cotranslational protein targeting to membrane. Predicted to be located in cytosol. Predicted to be part of signal recognition particle, endoplasmic reticulum targeting.

Source: NCBI Gene 6726 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 10 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 95.4% of screened cell lines (common-essential)
• MANE Select transcript: NM_003133

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11304
Approved symbol	SRP9
Name	signal recognition particle 9
Location	1q42.12
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143742
Ensembl biotype	protein_coding
OMIM	600707
Entrez	6726

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 11 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000304786, ENST00000366838, ENST00000366839, ENST00000619790, ENST00000626563, ENST00000650651, ENST00000651465, ENST00000651653, ENST00000651761, ENST00000861557, ENST00000924808, ENST00000924809, ENST00000924810

RefSeq mRNA: 2 — MANE Select: NM_003133 NM_001130440, NM_003133

CCDS: CCDS1546, CCDS44323

Canonical transcript exons

ENST00000304786 — 3 exons

Exon	Start	End
ENSE00000961765	225783300	225783368
ENSE00001442734	225777826	225778012
ENSE00003686398	225789240	225790464

Expression profiles

Bgee: expression breadth ubiquitous, 149 present calls, max score 99.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 70.9534 / max 2592.6961, expressed in 1816 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
8829	70.9534	1816

Top tissues by expression

149 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
embryo	UBERON:0000922	99.53	gold quality
ganglionic eminence	UBERON:0004023	99.53	gold quality
ventricular zone	UBERON:0003053	99.52	gold quality
endometrium	UBERON:0001295	99.41	gold quality
cortical plate	UBERON:0005343	99.40	gold quality
adrenal tissue	UBERON:0018303	99.33	gold quality
islet of Langerhans	UBERON:0000006	99.32	gold quality
corpus callosum	UBERON:0002336	99.24	gold quality
hypothalamus	UBERON:0001898	99.14	gold quality
calcaneal tendon	UBERON:0003701	99.13	gold quality
rectum	UBERON:0001052	99.11	gold quality
substantia nigra	UBERON:0002038	99.09	gold quality
amygdala	UBERON:0001876	99.08	gold quality
spinal cord	UBERON:0002240	99.08	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.08	gold quality
temporal lobe	UBERON:0001871	99.07	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	99.06	gold quality
smooth muscle tissue	UBERON:0001135	99.05	gold quality
gall bladder	UBERON:0002110	99.05	gold quality
Brodmann (1909) area 9	UBERON:0013540	99.04	gold quality
lymph node	UBERON:0000029	99.03	gold quality
right adrenal gland cortex	UBERON:0035827	99.02	gold quality
right adrenal gland	UBERON:0001233	99.01	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	99.01	gold quality
nucleus accumbens	UBERON:0001882	98.99	gold quality
caudate nucleus	UBERON:0001873	98.98	gold quality
left adrenal gland	UBERON:0001234	98.95	gold quality
putamen	UBERON:0001874	98.93	gold quality
telencephalon	UBERON:0001893	98.91	gold quality
adrenal gland	UBERON:0002369	98.91	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	41.59
E-GEOD-84465	yes	23.31
E-MTAB-10042	yes	10.84
E-MTAB-6819	no	4013.41
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

87 targeting SRP9, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 95.4% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 5)

• PSB7, PRDX1, and SRP9 up-regulation as candidate biomarkers of colon cancer is discovered (PMID:18549262)
• mutational study on SRP9/14 that identified and characterized regions and single residues essential for elongation arrest activity (PMID:20348448)
• Dats show that Alu RNA promotes functional binding of Signal Recognition Particle proteins SRP9/14 to 40S ribosomal subunits. (PMID:25697503)
• Investigation of SRP9 protein expression in breast cancer. (PMID:34727289)
• Significance of signal recognition particle 9 nuclear translocation: Implications for pancreatic cancer prognosis and functionality. (PMID:38847231)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	srp9	ENSDARG00000042851
mus_musculus	Srp9	ENSMUSG00000026511
rattus_norvegicus	Srp9	ENSRNOG00000003211
drosophila_melanogaster	Srp9	FBGN0035827
caenorhabditis_elegans		WBGENE00013984

Protein

Protein identifiers

Signal recognition particle 9 kDa protein — P49458 (reviewed: P49458)

All UniProt accessions (4): P49458, E9PE20, Q659G3, Q6P2S0

UniProt curated annotations — full annotation on UniProt →

Function. Component of the signal recognition particle (SRP) complex, a ribonucleoprotein complex that mediates the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). SRP9 together with SRP14 and the Alu portion of the SRP RNA, constitutes the elongation arrest domain of SRP. The complex of SRP9 and SRP14 is required for SRP RNA binding.

Subunit / interactions. Heterodimer with SRP14; binds RNA as heterodimer. Component of a signal recognition particle complex that consists of a 7SL RNA molecule of 300 nucleotides and six protein subunits: SRP72, SRP68, SRP54, SRP19, SRP14 and SRP9.

Subcellular location. Cytoplasm.

Similarity. Belongs to the SRP9 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P49458-1	1	yes
P49458-2	2

RefSeq proteins (2): NP_001123912, NP_003124* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008832	SRP9	Family
IPR009018	Signal_recog_particle_SRP9/14	Homologous_superfamily
IPR039432	SRP9_dom	Domain
IPR039914	SRP9-like	Family

Pfam: PF05486

UniProt features (15 total): strand 5, helix 3, turn 2, initiator methionine 1, chain 1, sequence conflict 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
5AOX	X-RAY DIFFRACTION	2.04
1E8O	X-RAY DIFFRACTION	3.2
7NFX	ELECTRON MICROSCOPY	3.2
4UYK	X-RAY DIFFRACTION	3.22
4UYJ	X-RAY DIFFRACTION	3.35
1E8S	X-RAY DIFFRACTION	4
1RY1	ELECTRON MICROSCOPY	12

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P49458-F1	90.41	0.85

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 52

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1799339	SRP-dependent cotranslational protein targeting to membrane
R-HSA-392499	Metabolism of proteins
R-HSA-72766	Translation

MSigDB gene sets: 228 (showing top): MORF_MTA1, MORF_MBD4, MODULE_151, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MODULE_150, MORF_HDAC1, GOBP_PROTEIN_TARGETING, MORF_RAD21, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, GOBP_REGULATION_OF_TRANSLATIONAL_ELONGATION, MORF_HDAC2, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, MODULE_149, MORF_PSMC2

GO Biological Process (2): SRP-dependent cotranslational protein targeting to membrane (GO:0006614), negative regulation of translational elongation (GO:0045900)

GO Molecular Function (4): RNA binding (GO:0003723), signal recognition particle binding (GO:0005047), 7S RNA binding (GO:0008312), protein binding (GO:0005515)

GO Cellular Component (6): signal recognition particle receptor complex (GO:0005785), signal recognition particle, endoplasmic reticulum targeting (GO:0005786), cytosol (GO:0005829), cytoplasm (GO:0005737), signal recognition particle (GO:0048500), ribonucleoprotein complex (GO:1990904)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Translation	1
Metabolism of proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
cellular anatomical structure	2
translation	1
cotranslational protein targeting to membrane	1
protein targeting to ER	1
translational elongation	1
regulation of translational elongation	1
negative regulation of translation	1
nucleic acid binding	1
ribonucleoprotein complex binding	1
RNA binding	1
binding	1
rough endoplasmic reticulum membrane	1
membrane protein complex	1
endoplasmic reticulum protein-containing complex	1
signal recognition particle	1
intracellular anatomical structure	1
ribonucleoprotein complex	1
protein-containing complex	1

Protein interactions and networks

STRING

2232 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SRP9	SRP14	P37108	999
SRP9	SRP72	O76094	999
SRP9	SRP19	P09132	999
SRP9	SRP68	Q9UHB9	999
SRP9	SRP54	P13624	997
SRP9	SRPRA	P08240	681
SRP9	SRPRB	Q9Y5M8	644
SRP9	COG3	Q96JB2	601
SRP9	PABPC1	P11940	580
SRP9	SPCS1	Q9Y6A9	570
SRP9	SZRD1	Q7Z422	531
SRP9	SEC61G	P38384	523
SRP9	HNRNPK	P61978	506
SRP9	SEC61A1	P38378	504
SRP9	SHMT1	P34896	496

IntAct

183 interactions, top by confidence:

A	B	Type	Score
SRP9	SRP14	psi-mi:“MI:0915”(physical association)	0.890
SRP14	SRP9	psi-mi:“MI:0915”(physical association)	0.890
SRP9	SRP72	psi-mi:“MI:0914”(association)	0.730
PTK2	TGFB1I1	psi-mi:“MI:0914”(association)	0.680
ACTN2	SRP9	psi-mi:“MI:0915”(physical association)	0.560
RYBP	SRP9	psi-mi:“MI:0915”(physical association)	0.560
SRP9	DPP9	psi-mi:“MI:0915”(physical association)	0.560
CDHR3	SRP9	psi-mi:“MI:0915”(physical association)	0.560
CC2D2A	OFD1	psi-mi:“MI:2364”(proximity)	0.420
SGCD	SRP9	psi-mi:“MI:0915”(physical association)	0.400
	TK2	psi-mi:“MI:0915”(physical association)	0.400
OTUB1		psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
Edc4	C4BPA	psi-mi:“MI:0914”(association)	0.350
EXOSC1	MPHOSPH6	psi-mi:“MI:0914”(association)	0.350
DUX4	CBX3	psi-mi:“MI:0914”(association)	0.350
E7	COPE	psi-mi:“MI:0914”(association)	0.350

BioGRID (525): SRP9 (Affinity Capture-MS), SRP9 (Affinity Capture-MS), SRP9 (Proximity Label-MS), SRP9 (Proximity Label-MS), SRP9 (Proximity Label-MS), SRP9 (Proximity Label-MS), SRP9 (Proximity Label-MS), SRP9 (Proximity Label-MS), SRP9 (Proximity Label-MS), SRP9 (Affinity Capture-MS), SRP9 (Affinity Capture-MS), SRP9 (Affinity Capture-MS), SRP9 (Affinity Capture-MS), SRP9 (Two-hybrid), SRP54 (Affinity Capture-MS)

ESM2 similar proteins: A0A140F3K6, A0A6M3VZT9, A0RVX7, A1KRS4, A4IR79, A4VSE9, A4VYN7, A8ALC5, A9A5J1, A9VI08, B1MXP9, B7IYP1, B8DCF0, C5D4Z2, I6WJ72, O26903, O27943, O29789, O30321, O32124, P0DW82, P18005, P41063, P49458, P51429, Q03R44, Q03YQ1, Q04ER0, Q0AZQ0, Q12NR2, Q16BB4, Q1WT33, Q2LQ83, Q2RHZ4, Q2W1Y0, Q3JYN3, Q47269, Q57778, Q5KWU6, Q65GS6

Diamond homologs: O04438, P21262, P34642, P49458, P49962, Q4R6I6, Q55GL2, Q9SMU7, Q9VSC1

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 139 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	6	10.2×	6e-03
Loss of proteins required for interphase microtubule organization from the centrosome	6	10.2×	6e-03
AURKA Activation by TPX2	6	9.8×	6e-03
Anchoring of the basal body to the plasma membrane	8	9.7×	1e-03
Recruitment of mitotic centrosome proteins and complexes	6	8.8×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

10 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	2
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

579 predictions. Top by Δscore:

Variant	Effect	Δscore
1:225778008:TGAAG:T	donor_loss	1.0000
1:225778013:GT:G	donor_loss	1.0000
1:225778014:T:G	donor_loss	1.0000
1:225783364:TAGTT:T	donor_gain	1.0000
1:225783366:GTT:G	donor_gain	1.0000
1:225783367:TT:T	donor_gain	1.0000
1:225783369:G:GG	donor_gain	1.0000
1:225783365:AGTT:A	donor_gain	0.9900
1:225783366:GTTG:G	donor_gain	0.9900
1:225783367:TTGT:T	donor_gain	0.9900
1:225783367:TTGTA:T	donor_loss	0.9900
1:225783368:TGTA:T	donor_loss	0.9900
1:225783369:G:A	donor_loss	0.9900
1:225783370:T:TG	donor_loss	0.9900
1:225783371:AA:A	donor_loss	0.9900
1:225783372:A:AA	donor_loss	0.9900
1:225783373:G:A	donor_loss	0.9900
1:225789238:A:AG	acceptor_gain	0.9900
1:225789239:G:GG	acceptor_gain	0.9900
1:225789239:GT:G	acceptor_gain	0.9900
1:225778105:G:GT	donor_gain	0.9800
1:225778142:T:G	donor_gain	0.9800
1:225783299:GGCAC:G	acceptor_gain	0.9800
1:225778866:TT:T	donor_gain	0.9700
1:225783298:A:AG	acceptor_gain	0.9700
1:225783299:G:GG	acceptor_gain	0.9700
1:225783293:GTTTC:G	acceptor_loss	0.9600
1:225783294:TTTCA:T	acceptor_loss	0.9600
1:225783295:TTCA:T	acceptor_loss	0.9600
1:225783297:CA:C	acceptor_loss	0.9600

AlphaMissense

572 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:225777959:T:A	W7R	0.999
1:225777959:T:C	W7R	0.999
1:225777968:T:C	F10L	0.999
1:225777969:T:C	F10S	0.999
1:225777970:C:A	F10L	0.999
1:225777970:C:G	F10L	0.999
1:225777981:C:A	A14D	0.999
1:225777961:G:C	W7C	0.998
1:225777961:G:T	W7C	0.998
1:225777980:G:C	A14P	0.998
1:225789249:T:G	Y51D	0.998
1:225783303:C:A	R26S	0.997
1:225783318:T:C	Y31H	0.997
1:225783318:T:G	Y31D	0.997
1:225789278:G:C	K60N	0.997
1:225789278:G:T	K60N	0.997
1:225789304:T:C	L69P	0.997
1:225783304:G:C	R26P	0.996
1:225783355:C:T	T43I	0.996
1:225789256:C:T	T53I	0.996
1:225777990:T:C	L17P	0.995
1:225783346:T:A	V40D	0.995
1:225777960:G:C	W7S	0.994
1:225777969:T:G	F10C	0.994
1:225783319:A:C	Y31S	0.994
1:225789274:T:A	V59E	0.994
1:225789276:A:G	K60E	0.994
1:225777968:T:A	F10I	0.993
1:225777992:T:G	Y18D	0.993
1:225789249:T:A	Y51N	0.993

dbSNP variants (sampled 300 via entrez): RS1000465567 (1:225781790 A>G), RS1000484206 (1:225785176 T>G), RS1000793867 (1:225781498 C>A), RS1000955648 (1:225778153 C>A,G,T), RS1001085638 (1:225783585 T>C), RS1001200822 (1:225783189 G>A), RS1001266450 (1:225784000 GT>G,GTT,GTTT), RS1001528845 (1:225780788 C>A), RS1001560052 (1:225781102 T>C), RS1001866036 (1:225789622 CAT>C), RS1002426753 (1:225788358 A>G), RS1002536818 (1:225779544 C>T), RS1002567846 (1:225779923 C>T), RS1002771108 (1:225786070 T>G), RS1002779553 (1:225784543 C>T)

Disease associations

OMIM: gene MIM:600707 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST003447_2	Neuroticism	2.000000e-08
GCST004607_209	Plateletcrit	2.000000e-09
GCST006464_3	Endometrial cancer	8.000000e-07
GCST009312_20	Antisaccade task score	5.000000e-06
GCST90002388_54	Lymphocyte count	2.000000e-13
GCST90002392_255	Mean corpuscular volume	5.000000e-13
GCST90002400_542	Plateletcrit	5.000000e-14
GCST90002401_405	Platelet distribution width	2.000000e-13
GCST90002402_264	Platelet count	1.000000e-09
GCST90002404_449	Red cell distribution width	1.000000e-12

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement
EFO:0007985	platelet crit
EFO:0007969	cognitive inhibition measurement
EFO:0004587	lymphocyte count
EFO:0007984	platelet component distribution width
EFO:0004309	platelet count
EFO:0009188	Red cell distribution width

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725084 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 3 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.27	Kd	5323	nM	CHEMBL3752910
5.27	ED50	5323	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 10 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149487: Binding affinity to human SRP9 incubated for 45 mins by Kinobead based pull down assay	kd	5.3228	uM

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression	4
sodium arsenite	decreases expression	2
Air Pollutants	affects expression, increases abundance, decreases expression	2
Particulate Matter	decreases expression, increases abundance, affects cotreatment	2
aristolochic acid I	decreases expression	1
bisphenol F	affects cotreatment, decreases expression	1
dicrotophos	decreases expression	1
terbufos	decreases methylation	1
beta-lapachone	decreases expression	1
arsenite	affects binding, increases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	increases abundance, increases expression	1
4-hydroxy-2-nonenal	affects binding	1
beta-methylcholine	affects expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
abrine	decreases expression	1
jinfukang	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Ethanol	increases abundance, affects cotreatment, decreases expression	1
Arsenic	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	decreases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652529	Binding	Binding affinity to human SRP9 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B3I6	Abcam HEK293T SRP9 KO	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.